Lilly’s Ebglyss shown to be effective in former Dupixent users
Contributor since / Followers
jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated with dupilumab, also known as Dupixent.
Lilly added that the study also showed Ebglyss was able to achieve meaningful improvements in patients with difficult-to-treat dermatitis on the face and hands.
The company said patients in the study who had discontinued dupilumab due to eye-related events, facial dermatitis or inflammatory arthritis did not report similar events while using Ebglyss, according to a statement.
Ebglyss received FDA approval in September for the treatment of adults and certain children aged 12 years and older with moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies.